BMA Braunschweigische Maschinenbauanstalt AG: new board line-up

Effective 1 May 2023, Dr Arend Wittenberg will be the new CEO of the company

New line-up at BMA Braunschweigische Maschinenbauanstalt AG: the Supervisory Board has appointed Dr Arend Wittenberg as new CEO of the company. CEO Dr Dirk Steinbrink and CTO Uwe Schwanke will both be leaving BMA this year, the former at his own request, the latter is retiring.

Dr Arend Wittenberg responsible for Sales, Engineering and R&D

The BMA Supervisory Board is delighted to announce the appointment of Dr Arend Wittenberg as CEO of the company. Dr Wittenberg will be responsible for Sales, Engineering, and Research and Development from May 2023. He can look back on more than 20 successful years and a range of management positions in the international sugar sector.

Long-lasting relationship with BMA in another capacity

Dr Wittenberg: “I have always been fascinated by the development of sugar processes and the related technology. My professional relationship with BMA as a customer spans several years. Now I very much look forward to making a direct contribution to BMA’s work, helping this well-established yet innovative company continue its success in the global market.”

Dr Dirk Steinbrink and Uwe Schwanke to leave BMA

Dr Dirk Steinbrink will be leaving the company at his own request. Mr Uwe Schwanke will temporarily assume responsibility for the commercial departments and project management. Although he is due to retire on 30 September 2023, Mr Schwanke will continue to support BMA in an advisory capacity.

“Outstanding manager and sugar technology expert”

Chairman of the Supervisory Board Dr Puhlmann thanked the outgoing member of the board: “Dr Steinbrink has made a valuable contribution to the sustainable development of BMA. I am delighted to welcome Dr Wittenberg, an outstanding manager and sugar technology expert, to the Board of Directors and wish the new board the very best of success.”

Challenges: decarbonisation, energy efficiency and an international profile

Dr Nicolas Himmelmann, a partner at the majority shareholder AUCTUS, added: “We look forward to a good collaboration with Dr Wittenberg, supporting BMA on its development path, meeting the market challenges of decarbonisation and energy efficiency together with our customers, as well as further expanding BMA’s activities in sugar cane processing across the globe.”